A multicenter randomized placebo-controlled trial evaluating daidzein-rich isoflavone aglycones in endometriosis-associated dysmenorrhea
This multicenter randomized placebo-controlled trial suggests that daidzein-rich isoflavone aglycones (DRIAs) offer a safe, non-hormonal therapeutic option for endometriosis-associated dysmenorrhea, demonstrating a statistically significant pain reduction at Month 3 and a consistent trend toward efficacy without suppressing ovarian function.